FRA:MRK - Merck KGaA Stock Price, News, & Analysis

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company also has collaboration with the Solvias to offer the PyroMAT system, a MAT kit for pyrogen detection; Immutep Limited; Leap Therapeutics, Inc.; Pfizer Inc.; and Personal Genome Diagnostics Inc. In addition, MERCK Kommanditgesellschaft auf Aktien has a clinical research collaboration with Daiichi Sankyo Company, Limited to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate; and a strategic alliance with genOway S.A. to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Merck KGaA (FRA:MRK) Frequently Asked Questions

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What price target have analysts set for MRK?

21 Wall Street analysts have issued 1-year price objectives for Merck KGaA's shares. Their predictions range from €78.00 to €115.00. On average, they expect Merck KGaA's stock price to reach €98.80 in the next year. This suggests a possible upside of 1.9% from the stock's current price. View Analyst Price Targets for Merck KGaA.

What is the consensus analysts' recommendation for Merck KGaA?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 2 sell ratings, 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

Media coverage about MRK stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck KGaA earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the healthcare company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include Acreage (ACRGF), Amryt Pharma (AMYT), Benchmark (BMK), Cannabis Science (CBIS), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF), Cosmos (COSM), Curaleaf (CURLF), Diurnal Group (DNL), Easton Pharmaceuticals (EAPH), Evgen Pharma (EVG), EVIO (EVIO), Evotec (EVT) and Flower One (FLOOF).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:

• Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
• Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
• Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
• Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
• Ms. Belén Garijo López, CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €96.92.

What is Merck KGaA's official website?

The official website for Merck KGaA is https://www.merckgroup.com/.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.